Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial

Burns, DK; Alexander, RC; Welsh-Bohmer, KA; Culp, M; Chiang, C; O'Neil, J; Evans, RM; Harrigan, P; Plassman, BL; Burke, JR; Wu, J; Lutz, MW; Haneline, S; Schwarz, AJ; Schneider, LS; Yaffe, K; Saunders, AM; Ratti, E; Aarsland, D; Ackermann, O; Agron-Figueroa, J; Arnold, T; Bailey, P; Ballard, C; Barton, S; Belden, C; Bergthold, J; Bond, W; Bradley, R; Braude, W; Brody, M; Brown, R; Burke, J; Butchart, J; Campbell, T; Carusa, S; Clarnette, R; Cohen, R; Connelly, P; Copeland, J; Coulthard, E; Crusey, J; Curtis, C; De Sanctis, V; Demakis, G; Denburg, N; Donikyan, M; Doody, R; Ellenbogen, A; Fleischman, D; Raymont, V

Journal article

Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial

Abstract:: Background: The identification of people at risk of cognitive impairment is essential for improving recruitment in secondary prevention trials of Alzheimer's disease. We aimed to test and qualify a biomarker risk assignment algorithm (BRAA) to identify participants at risk of developing mild cognitive impairment due to Alzheimer's disease within 5 years, and to evaluate the safety and efficacy of low-dose pioglitazone to delay onset of mild cognitive impairment in these at-risk participants. ...
Expand abstract
Collapse abstract

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Burns, D. K., Alexander, R. C., Welsh-Bohmer, K. A., Culp, M., Chiang, C., O'Neil, J., Evans, R. M., Harrigan, P., Plassman, B. L., Burke, J. R., Wu, J., Lutz, M. W., Haneline, S., Schwarz, A. J., Schneider, L. S., Yaffe, K., Saunders, A. M., Ratti, E., Aarsland, D., … Raymont, V. (2021). Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurology, 20(7), 537–547.

MLA Style

Burns, D. K., et al. “Safety and Efficacy of Pioglitazone for the Delay of Cognitive Impairment in People at Risk of Alzheimer's Disease (TOMMORROW): a Prognostic Biomarker Study and a Phase 3, Randomised, Double-Blind, Placebo-Controlled Trial.” Lancet Neurology, vol. 20, no. 7, Elsevier, 2021, pp. 537–47.

Chicago Style

Burns, DK, RC Alexander, KA Welsh-Bohmer, M Culp, C Chiang, J O'Neil, RM Evans, et al. 2021. “Safety and Efficacy of Pioglitazone for the Delay of Cognitive Impairment in People at Risk of Alzheimer's Disease (TOMMORROW): a Prognostic Biomarker Study and a Phase 3, Randomised, Double-Blind, Placebo-Controlled Trial.” Lancet Neurology 20 (7): 537–47.
Share
Print